Stick With DENTSPLY Sirona Inc (XRAY). The Bull Are Alive And Well

Currently, there are 207.20M common shares owned by the public and among those 205.37M shares have been available to trade.

The company’s stock has a 5-day price change of -3.08% and -10.56% over the past three months. XRAY shares are trading -10.56% year to date (YTD), with the 12-month market performance down to -17.45% lower. It has a 12-month low price of $26.27 and touched a high of $43.24 over the same period. XRAY has an average intraday trading volume of 2.85 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.16%, -5.52%, and -8.82% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of DENTSPLY Sirona Inc (NASDAQ: XRAY) shares accounts for 105.00% of the company’s 207.20M shares outstanding.

It has a market capitalization of $6.60B and a beta (3y monthly) value of 0.99. The earnings-per-share (ttm) stands at -$0.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.81% over the week and 2.08% over the month.

Analysts forecast that DENTSPLY Sirona Inc (XRAY) will achieve an EPS of $0.42 for the current quarter, $0.54 for the next quarter and $2.41 for 2025. The lowest estimate earnings-per-share for the quarter is $0.4 while analysts give the company a high EPS estimate of $0.45. Comparatively, EPS for the current quarter was $0.39 a year ago. Earnings per share for the fiscal year are expected to increase by 12.60%, and 17.31% over the next financial year. EPS should shrink at an annualized rate of 14.10% over the next five years, compared to 32.70% over the past 5-year period.

Looking at the support for the XRAY, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on February 26, 2024, with the firm’s price target at $42. Needham coverage for the DENTSPLY Sirona Inc (XRAY) stock in a research note released on November 16, 2023 offered a Buy rating with a price target of $35. William Blair on their part issued Underperform rating on August 05, 2022.

Most Popular

Related Posts